A comprehensive Chronic Inflammatory Demyelinating Polyneuropathy Market analysis highlights the increasing awareness and improved diagnostic capabilities as primary factors driving market growth. As healthcare professionals gain a deeper understanding of this complex neurological disorder, earlier and more accurate diagnoses are being achieved, consequently increasing the identified patient population requiring chronic, high-cost therapies. CIDP, being an orphan disease in many regions, commands premium pricing for its core treatments.

The Chronic Inflammatory Demyelinating Polyneuropathy Market analysis reveals that the market is currently dominated by established immunotherapies, specifically Intravenous Immunoglobulin (IVIg), which serves as the first-line and maintenance therapy for many patients. The high cost and ongoing requirement for IVIg infusions, often administered in hospitals or specialized clinics, ensure a sustained, high-revenue stream for the pharmaceutical companies that dominate the plasma-derived therapeutics segment, such as CSL Behring and Grifols.